Alex A. Petrakian, M.D., F.A.C.C.

Address
115 W. Fifth Street
Tyler, TX 75703

Telephone: (903) 595-2283
Fax: (903) 597-2238

Private Practice

• 2000-Present: Cardiovascular Associates of East Texas, P.A., Tyler, Texas

Education

• 1971-1986: College Louise Wegmann, Beirut, Lebanon, French Baccalaureate with Honors

Academic Degrees

• 1986-1989: American University of Beirut, Beirut, Lebanon, Bachelor of Sciences in Biology with distinction
• 1989-1993: American University of Beirut, Beirut, Lebanon, Doctor of Medicine

Post Graduate Training

Internal Medicine Residency

• 1993-1996: Baylor College of Medicine, Houston, TX

Cardiology Fellowship

• 1996-1999: Baylor College of Medicine, Houston, TX

Cardiac Electrophysiology Fellowship

• 1999-2000: Baylor College of Medicine, Houston, TX

Board Certification

• 2000: Nuclear Cardiology Board Certification
• 2000: American Board of Internal Medicine – Cardiac Electrophysiology
• 1999: American Board of Internal Medicine – Cardiovascular Diseases
• 1997: American Board of Internal Medicine
• 1993: Education Commission for Foreign Medical Graduates (ECFMG)

Licensure and Certification

• 2001: Nuclear Radiation Certification State of Texas #L04800
• 1997-Present: Texas State Board of Medical Examiners K6234

Hospital Appointments

• 2000- Present: Acting Staff - Trinity Mother Frances Hospital, Tyler, Texas
• 2000 – Present: Acting Staff - East Texas Medical Center Hospital, Tyler, Texas
• 2000 – Present: Consulting - East Texas Medical Center Hospital, Quitman, Texas
• 2000 – Present: Consulting - East Texas Medical Center Hospital, Crockett, Texas
• 2000 – Present: Consulting - East Texas Medical Center Hospital, Mount Vernon, Texas
• 2000 – Present: Consulting - East Texas Medical Center Hospital, Jacksonville, Texas
• 2000 – Present: Consulting - East Texas Medical Center Hospital, Athens, Texas
• 2000 – Present: Consulting - Laird Memorial Hospital, Kilgore, Texas

Professional Societies and Other Memberships

• Fellow, American College of Cardiology
• Diplomate of the American Board of Internal Medicine
• Diplomate of the American Board of Internal Medicine-Cardiology
• Diplomate of the American Board of Internal Medicine – Cardiac Electrophysiolgy

• Primary Investigator – CRT RENEWAL Registry - “Cardiac Resynchronization Therapy Registry Evaluating Patient Response with RENEWAL Family Devices (CRT RENEWAL Registry)”
• Primary Investigator – ACT Registry - A prospective, outcome-oriented registry of all patients implanted with an SJM ICD and to evaluate the utilization of advanced features in patients with current ICD indications.
• Primary Investigator – OMNI Study - Post-market observational study conducted in the United states.  The purpose of the OMNI study is to characterize therapy and diagnostic utilization in study participants implanted with study devices and to describe ICD therapy utilization for life threatening arrhythmias in primary and secondary prevention study participants.
• Primary Investigator – PEGASUS Study – “Pacing Evaluation – Atrial SUpport Study in Cardiac Resynchronization Therapy”   (PEGASUS CRT Study)
• Co-Investigator – OPTIMUM Registry - A prospective, outcome-oriented registry of patients implanted with SJM OptimTM leads.  This registry evaluated the chronic performance of the market-released SJM Cardiac Rhythm Management (CRM) leads with OptimTM insulation material.
• Co-Investigator – RE-LY - Randomized Evaluation of Long term anticoagulant therapy (RE-LY) comparing the efficacy and safety of two blinded doses of dabigatran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, parallel-group, non-inferiority trial.
• Co-Investigator – ASPEN - ASPEN --“AF Suppression Pacing to Prevent First Episode of Atrial Fibrillation in High Risk Patients”-- Study.
• Co-Investigator – ENDEAVOR IV – A Randomized, Controlled Trial of the Medtronic Endeavor Drug Eluting Coronary Stent System versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions.
• Co-Investigator – A-HeFT - A Placebo-Controlled Trial of Bidil Added to Standard Therapy In African-American Patients with Heart Failure.
• Co-Investigator – TRENDS - A prospective, non-randomized, multi-center trial in subjects implanted with a commercially available Medtronic implantable pulse generator (IPG), implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) device. The primary purpose of the trial is to determine if the device trending data are indicators of clinical outcomes in subjects with atrial tachyarrhythmias.
• Co-Investigator – ACCOMPLISH - A prospective, multicenter, double-blind, randomized, active-controlled trial to compare the effects of Lotrel (amlodipine/benazepril to benazepril and hydrochlorothiazide combined on the reduction of cardiovascular morbidity and mortality in patients with high risk hypertension.
  Co-Investigator - AMIHOT II – A prospective, Multi-center, randomized study of Aqueous Oxygen Therapy for 90 minutes in Anterior Acute MI patients with successful PCI/stenting presenting within 6 hours from time of symptom onset until time of reperfusion.
  Co-Investigator – TIMI38/TRITON – A Comparison of CS-747 and Clopidrogrel in Acute Coronary Syndrome Patients who are to Undergo Percutaneous Coronary Intervention; a Phase III, multicenter, randomized, parallel-group, double-dummy, active controlled trial in patients with acute coronary syndrome (ACS), who are to undergo percutaneous coronary intervention (PCI).
  Co-Investigator - ULTRA study- Ventricular Automatic Capture assessment Study.
• Co-Investigator – VISION 305 - “Vasodilator Induced Stress In Concordance with Adenosine” A multicenter, risk-stratified, randomized, double-blind, double-dummy study drug administration, active-controlled, complete two-arm crossover study with a reference third arm.
• Co-Investigator - APEX-AMI - “A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of Pexelizumab in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.” (Assessment of PEXelizumab in Acute Myocardial Infarction)-APEX-AMI.
• Investigator  - ASSIST – Atrial Tachyarrhythmia Suppression Strategy in ICD Subjects Trial
• Investigator  -  RIATA – Evaluation of Riata Integrated and Dedicated Bipolar Leads with CRT devices.
• Investigator—MAVRIC-- MArquis/Maximo VR ICD Programming Practices Registry
• Investigator- MASTER-- Microvolt T Wave AlternanS TEsting for Risk Stratification of Post MI Patients
• Investigator – WAVE –World wide application study of Marquis VR enhancements. A global prospective, non-randomized, multicenter trial that  focuses on the wavelet dynamic discrimination criterion by use of the Marquis VR model 7230 implantable cardioverter defibrillator (ICD).
• Investigator – VAST –     Ventricular arrhythmia suppression trial. A randomized, single-blinded, crossover, comparative trial of the rate smoothing  feature. Of  Guidant Prism and Prism II  Automatic implantable cardio defibrillator.
• Participant - ALIVE – The Azimilide Post - infarct Survival Evaluation
• Participant - PURSUIT – Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy
• Participant – AFFIRM – Atrial Fibrillation Follow-up Investigation of Rhythm Management
• Co-Investigator - A prospective, non-randomized, multi-center trial in subjects implanted with a commercially available Medtronic implantable pulse generator (IPG), implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) device. The primary purpose of the trial is to determine if the device trending data are indicators of clinical outcomes in subjects with atrial tachyarrhythmias.
• Co-Investigator—ACUITY Trial- A randomized comparison of Angiomax (bivalirudin) versus Lovenox/Clexane (enoxaparin) in patients undergoing early invasive management for acute coronary syndrome with our ST-segment elevation.
• Co-Investigator - AWARE -- Analysis of a New AT/AF Detection Algorithm in   Patients with Atrial Arrhythmias.
• Co–Investigator - LESS - Lower Energy Safety Study
• Co-Investigator - GUSTO IV AMI (Protocol CO116T31): A Phase III, randomized, open-label trial evaluating the efficacy and safety of. ReoPro™ (ABCIXIMAB) in combination with reduced dose  Retavase™/Rapilysin™ (Recombinant Plasminogen Activator, Reteplase, r-PA) for the treatment of acute myocardial infarction.
• Co-Investigator - AMISTAD II Trial (Phase III): A randomized, double-blind, placebo-controlled, multicenter trial to evaluate the efficacy and safety of Adenosine (Pallacor, Adenosine Injection) as an adjunct to reperfusion therapy (Thrombolysis or Mechanical Reperfusion) in the treatment of acute anterolateral myocardial infarction.
• Co-Investigator - VALIANT Trial Phase III (VALsartan In Acute myocardial iNfarcTion): A multinational, multicenter, double-blind, randomized, active controlled, parallel group study comparing the efficacy and safety of long-term treatment with Valsartan, Captopril and their combination in high risk patients after myocardial infarction.
• Co-Investigator – VALIANT REGISTRY SUBSTUDY : VALIANT Trial Phase III (VALsartan In Acute myocardial iNfarcTion): A multinational, multicenter, double-blind, randomized, active controlled, parallel group study comparing the efficacy and safety of long-term treatment with Valsartan, Captopril and their combination in high risk patients after myocardial infarction.  
• Co-Investigator – EPHESUS – IE-99-02-035, Clinical protocol for a double blind, randomized, placebo-controlled trial to evaluating the safety and efficacy of eplerenone in patients with heart failure following acute myocardial infarction
• Co-Investigator - OCTAVE - CV137-120 Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril (OCTAVE) A Phase III, Randomized, Double Blind, Active Controlled Comparision of Omapatrilat and Enalapril in Subjects with newly Diagnosed or Established Hypertension
• Co-Investigator – REPLACE – TMC-BIV-00-01, Randomized Evaluation in Percutaneous Coronary Intervention Linking Angiomax to Reduced Clinical Events.
• Co-Investigator -  REPLACE II - A Randomized Evaluation in PCI Linking 
  Angiomax to Reduced Clinical Events, Part 2:  REPLACE-2 (TMC-BIV-01-03)
• Co-Investigator – SYNERGY- A Prospective, Randomized, Open-Label, Multicenter Study in Patients Presenting with Acute Coronary Syndromes, Aventix Pharmaceuticals Protocol Number ENO.GMA.301.IND# 31532
• Co-Investigator – A Double-Blind Comparison Of The Incidence Of Hypotension With Two Formulations Of Intravenous Amiodarone:  CordaroneÒ I.V. vs Amiodarone Aqueous I.V. Injection - Protocol No. 058K1-312-US 
• Co-Investigator – CRISP - A single Arm, Open label Study of Cervastatin (Baycol®) in Community based Patients with Hypercholesterolemia at risk for Cardiovascular Disease and patients with Cardiovascular Disease.  To Monitor inflammatory markers
• Co-Investigator-INSPIRE :A  Randomized, Prospective Multicenter Trial Evaluating The Role Of Adenosine Tc99m Sestamibi SinglepPhoton Emission Computed Tomography For Assessing Risk And Therapeutic Outcomes In Survivors Of Acute Myocardial Infarction.
• Co-Investigator – Otsuka Protocol 21-98-214-01 CASTLE “ A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Arm, Study to Asses The Long-Term Effects of Pletal® (Cilostazol) Versus Placebo Administered Orally to Patients with Intermittent Claudication Secondary to Peripheral Arterial Disease”.
• Co-Investigator – AMIHOT – TherOx Aqueous Oxygen System – Acute Myocardial Infarction with Hyperoxemic Therapy “AMIHOT” Phase II clinical trial. A Randomized, Controlled, Multicenter Trial of Aqueous Oxygen Infusion for 90 Minutes Post-Primary PTCA/Stent Intervention in Acute Myocardial Infarction Patients.
• Co-Investigator - Extra Point.  Protocol # S1710202. Cardiovascular Safety Study of Nicotine Transdermal System.
• Co-Investigator - XIENCE™ V:  Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study sponsored by Abbott Vascular Inc.

Publications

• Badruddin SM, Ahmad A, Petrakian AA, He ZX, Mahmarian JJ, Verani MS. Identification of left main and three vessel coronary artery disease by adenosine myocardial tomography. Proceedings of American College of Cardiology 46th Annual meeting, J Am Coll Cardiol 1997; 29 (SuppI A):262A
• Petrakian AA, Ahmad A, Badruddin SM, He ZX, Lakkis NM,   Mahmarian JJ, Verani MS. Value of myocardial perfusion tomography in the assessment of post-stenting coronary restenosis. Proceedings of American College of Cardiology 46th Annual meeting, J Am Coll Cardiol 1997; 29 (Suppl A):228A
• Abmad A, Badruddin SM, Petrakian AA He ZX, Mahmarian JJ, Verani MS. Exercise SPECT versus exercise ECG testing for diagnosis of coronary artery disease in asymptomatic patients. Proceedings of American College of Cardiology 46th Annual meeting, J Am Coll Cardiol 1997; 29 (Suppl A):261A
• Precipitating factors for accelerating ventricular tachycardia during anti­tachycardia pacing. Dennis W.X. Zhu, Huabin Sun, Alexandre A. Petrakian.
  Baylor College of Medicine. Houston, TX, USA.
• Abstract presented at the European Society of Cardiology jn Vienna, 1998
• Optimal coupling interval of antitachycardia pacing for termination of rapid ventricula tachycardia. Dennis W.X. Zhu, Huabin Sun, Alexandre A. Petrakian. Baylor College of Medicine, Houston, TX, USA.
• Abstract presented at tile European Society of Cardiology in Vienna, 1998
• Electrophysiological testing in patients undergoing ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Alexandre Petrakian, MD; William Spencer III, MD, Nasser Lakkis, MD, Huabin Sun, MD, Michael Gollob, MD, Donna Killip, RN. John Payne, MD
• Abstract presented at NASPE, 1999
• A comparison of T-wave alternans and electrophysiologic testing as   a predictor of increased risk for sudden death in hypertrophic cardiomyopathy. Michael Gollob, MD, John Seger, MD, Jagaro Nattamma, MD, Alexandre Petrakian, MD, Kiran Jayaram, MD, Donna Killip, RN, William Spencer III, MD, Baylor College of Medicine, Houston.
• Abstract presented at NASPE 2000.
• Assessment for ventricular arrhythmia substrate following Ethanol-induced septal infarction in hypertrophic obstructive cardiomyopathy. Michael Gollob, MD, John Seger, MD, Jagaro Nattamma, MD, Alexandre Petrakian, MD, Kiran Jayaram, MD, Donna Killip, RN, William Spencer III, MD, Baylor College of Medicine, Houston.
• Abstract presented at NASPE 2000.

Languages

• English
• French
• Arabic
• Medical Spanish

Awards received

• French Baccalaureate (1986) with Honors
• Dean's Honor list throughout College
• B.S., in Biology with distinction (1989)
• Dean's Honor list throughout medical school
• MD with distinction (1993)
• Van Reet Award (2000)